Plain-English translation of NCT07394387 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating triple-negative breast cancer, an aggressive form of the disease. Researchers want to see if using high-intensity focused ultrasound (a technique that uses sound waves to destroy tumor tissue) combined with (a medication that helps your immune system fight cancer) before chemotherapy can improve how many patients achieve a complete response to treatment.
Triple-negative breast cancer is harder to treat than other types of breast cancer because standard hormone therapies don't work against it. This trial is exploring whether adding immune-boosting treatment before chemotherapy might help more patients have better outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive one initial treatment with focused sound waves to target your tumor. Depending on which group you're assigned to, you may also receive an immune-boosting injection either before or alongside your chemotherapy. Then you would receive six cycles of chemotherapy medication ( and ) combined with the immune medication over several months. Throughout the trial, you would have regular doctor visits, blood tests, and imaging scans to monitor how you're responding to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China